Research ExplorerPublicationsTherapeutic options in pulmonary hepatic vascular diseases

Therapeutic options in pulmonary hepatic vascular diseases

Standard

Therapeutic options in pulmonary hepatic vascular diseases. / Horvatits, Thomas; Fuhrmann, Valentin.

In: EXPERT REV CLIN PHAR, Vol. 7, No. 1, 01.01.2014, p. 31-42.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Horvatits, T & Fuhrmann, V 2014, 'Therapeutic options in pulmonary hepatic vascular diseases', EXPERT REV CLIN PHAR, vol. 7, no. 1, pp. 31-42. https://doi.org/10.1586/17512433.2014.857598

APA

Horvatits, T., & Fuhrmann, V. (2014). Therapeutic options in pulmonary hepatic vascular diseases. EXPERT REV CLIN PHAR, 7(1), 31-42. https://doi.org/10.1586/17512433.2014.857598

Vancouver

Horvatits T, Fuhrmann V. Therapeutic options in pulmonary hepatic vascular diseases. EXPERT REV CLIN PHAR. 2014 Jan 1;7(1):31-42. https://doi.org/10.1586/17512433.2014.857598

Bibtex

@article{07596f68af014ce881996a8b8c91efef,
title = "Therapeutic options in pulmonary hepatic vascular diseases",
abstract = "Pulmonary-hepatic vascular disorders are frequent complications in patients with portal hypertension and cirrhosis. Both hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) are associated with increased morbidity and mortality. The diagnosis of HPS should be confirmed early by arterial blood gas analysis and contrast enhanced echocardiography whereas POPH is finally diagnosed by presence of pulmonary arterial hypertension evaluated via right heart catheterization and presence of portal hypertension. Therapeutic options are initiation of long term oxygen therapy and liver transplantation in patients with severe HPS. Patients with POPH should receive targeted medical therapies with endothelin receptor antagonists, phosphodiesterase-5 inhibitors and/or prostanoids. In contrast, β-blockers should be avoided. It is unclear whether liver transplantation cures POPH or not. This review summarizes current knowledge of underlying conditions and focuses on therapeutic options in patients with pulmonary-hepatic vascular disorders.",
author = "Thomas Horvatits and Valentin Fuhrmann",
year = "2014",
month = jan,
day = "1",
doi = "10.1586/17512433.2014.857598",
language = "English",
volume = "7",
pages = "31--42",
journal = "EXPERT REV CLIN PHAR",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Therapeutic options in pulmonary hepatic vascular diseases

AU - Horvatits, Thomas

AU - Fuhrmann, Valentin

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Pulmonary-hepatic vascular disorders are frequent complications in patients with portal hypertension and cirrhosis. Both hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) are associated with increased morbidity and mortality. The diagnosis of HPS should be confirmed early by arterial blood gas analysis and contrast enhanced echocardiography whereas POPH is finally diagnosed by presence of pulmonary arterial hypertension evaluated via right heart catheterization and presence of portal hypertension. Therapeutic options are initiation of long term oxygen therapy and liver transplantation in patients with severe HPS. Patients with POPH should receive targeted medical therapies with endothelin receptor antagonists, phosphodiesterase-5 inhibitors and/or prostanoids. In contrast, β-blockers should be avoided. It is unclear whether liver transplantation cures POPH or not. This review summarizes current knowledge of underlying conditions and focuses on therapeutic options in patients with pulmonary-hepatic vascular disorders.

AB - Pulmonary-hepatic vascular disorders are frequent complications in patients with portal hypertension and cirrhosis. Both hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) are associated with increased morbidity and mortality. The diagnosis of HPS should be confirmed early by arterial blood gas analysis and contrast enhanced echocardiography whereas POPH is finally diagnosed by presence of pulmonary arterial hypertension evaluated via right heart catheterization and presence of portal hypertension. Therapeutic options are initiation of long term oxygen therapy and liver transplantation in patients with severe HPS. Patients with POPH should receive targeted medical therapies with endothelin receptor antagonists, phosphodiesterase-5 inhibitors and/or prostanoids. In contrast, β-blockers should be avoided. It is unclear whether liver transplantation cures POPH or not. This review summarizes current knowledge of underlying conditions and focuses on therapeutic options in patients with pulmonary-hepatic vascular disorders.

U2 - 10.1586/17512433.2014.857598

DO - 10.1586/17512433.2014.857598

M3 - SCORING: Journal article

C2 - 24308785

VL - 7

SP - 31

EP - 42

JO - EXPERT REV CLIN PHAR

JF - EXPERT REV CLIN PHAR

SN - 1751-2433

IS - 1

ER -